KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) issued its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.29), Yahoo Finance reports.
KalVista Pharmaceuticals Stock Performance
Shares of KALV stock opened at $13.04 on Friday. The firm’s 50 day moving average is $11.86 and its 200 day moving average is $12.45. KalVista Pharmaceuticals has a 12 month low of $7.21 and a 12 month high of $16.88.
Insider Activity at KalVista Pharmaceuticals
In related news, CEO Benjamin L. Palleiko sold 21,959 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $11.76, for a total transaction of $258,237.84. Following the sale, the chief executive officer now directly owns 216,387 shares in the company, valued at approximately $2,544,711.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Benjamin L. Palleiko sold 21,959 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $11.76, for a total transaction of $258,237.84. Following the sale, the chief executive officer now directly owns 216,387 shares in the company, valued at approximately $2,544,711.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Benjamin L. Palleiko sold 7,465 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $11.53, for a total transaction of $86,071.45. Following the sale, the chief executive officer now owns 224,547 shares in the company, valued at $2,589,026.91. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 37,512 shares of company stock worth $439,424. 12.30% of the stock is owned by corporate insiders.
Analyst Ratings Changes
Get Our Latest Research Report on KalVista Pharmaceuticals
About KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Read More
- Five stocks we like better than KalVista Pharmaceuticals
- Investing in Construction Stocks
- Why This Banking Stock Might Be Nearing the Bottom of Its Cycle
- 3 Grocery Stocks That Are Proving They Are Still Essential
- MarketBeat Week in Review – 7/8 – 7/12
- The Role Economic Reports Play in a Successful Investment Strategy
- Top 3 Beverage Stocks: Summer Earnings Reveal Key Trends
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.